| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| tau Proteins | 22 | 2019 | 239 | 3.830 |
Why?
|
| Neurodegenerative Diseases | 11 | 2016 | 281 | 1.770 |
Why?
|
| Drosophila Proteins | 12 | 2016 | 770 | 1.760 |
Why?
|
| Primary Health Care | 5 | 2023 | 801 | 1.760 |
Why?
|
| Drosophila melanogaster | 12 | 2016 | 843 | 1.710 |
Why?
|
| Parkinson Disease | 9 | 2025 | 739 | 1.390 |
Why?
|
| Tauopathies | 6 | 2014 | 76 | 1.200 |
Why?
|
| Physician Assistants | 3 | 2020 | 78 | 1.180 |
Why?
|
| alpha-Synuclein | 7 | 2018 | 134 | 1.170 |
Why?
|
| Drosophila | 13 | 2017 | 824 | 1.120 |
Why?
|
| Alzheimer Disease | 13 | 2025 | 866 | 1.000 |
Why?
|
| Disease Models, Animal | 16 | 2016 | 4690 | 0.890 |
Why?
|
| Eye | 7 | 2016 | 236 | 0.810 |
Why?
|
| Genes, Modifier | 2 | 2012 | 16 | 0.750 |
Why?
|
| Evidence-Based Practice | 2 | 2020 | 115 | 0.740 |
Why?
|
| Continuity of Patient Care | 1 | 2023 | 152 | 0.700 |
Why?
|
| Essential Tremor | 2 | 2022 | 94 | 0.650 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 386 | 0.610 |
Why?
|
| Nerve Degeneration | 5 | 2009 | 131 | 0.610 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2013 | 192 | 0.600 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 697 | 0.600 |
Why?
|
| Glycogen Synthase Kinase 3 | 5 | 2011 | 62 | 0.580 |
Why?
|
| Peptides | 5 | 2011 | 844 | 0.580 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 50 | 0.580 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 97 | 0.560 |
Why?
|
| Animals, Genetically Modified | 11 | 2016 | 341 | 0.560 |
Why?
|
| Aging | 4 | 2016 | 1254 | 0.550 |
Why?
|
| Handwriting | 1 | 2017 | 8 | 0.540 |
Why?
|
| Resistance Training | 1 | 2017 | 32 | 0.520 |
Why?
|
| Quality of Health Care | 4 | 2023 | 424 | 0.510 |
Why?
|
| Preventive Health Services | 1 | 2017 | 63 | 0.500 |
Why?
|
| Home Care Services | 1 | 2017 | 75 | 0.500 |
Why?
|
| United States Department of Veterans Affairs | 7 | 2019 | 694 | 0.500 |
Why?
|
| Disease Management | 2 | 2019 | 565 | 0.490 |
Why?
|
| Patients | 1 | 2016 | 129 | 0.480 |
Why?
|
| Genetic Testing | 3 | 2012 | 1099 | 0.470 |
Why?
|
| Animals | 38 | 2019 | 34850 | 0.460 |
Why?
|
| Electronic Health Records | 1 | 2022 | 804 | 0.440 |
Why?
|
| Neurofibrillary Tangles | 4 | 2014 | 27 | 0.440 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2017 | 255 | 0.440 |
Why?
|
| Pigmentation | 2 | 2012 | 36 | 0.430 |
Why?
|
| Chorea | 1 | 2014 | 39 | 0.420 |
Why?
|
| Gait | 1 | 2015 | 141 | 0.420 |
Why?
|
| Humans | 65 | 2025 | 132247 | 0.420 |
Why?
|
| Genomics | 2 | 2012 | 1652 | 0.410 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 1997 | 0.410 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 361 | 0.410 |
Why?
|
| Autophagy | 2 | 2014 | 426 | 0.400 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 430 | 0.400 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 414 | 0.390 |
Why?
|
| Memory Disorders | 1 | 2014 | 210 | 0.390 |
Why?
|
| Neuroglia | 1 | 2014 | 214 | 0.390 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 608 | 0.380 |
Why?
|
| Memory | 2 | 2014 | 356 | 0.370 |
Why?
|
| Retinal Photoreceptor Cell Inner Segment | 1 | 2011 | 4 | 0.370 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2014 | 166 | 0.370 |
Why?
|
| Research Design | 1 | 2016 | 743 | 0.370 |
Why?
|
| Huntington Disease | 3 | 2010 | 143 | 0.360 |
Why?
|
| Amyloid beta-Peptides | 5 | 2019 | 234 | 0.360 |
Why?
|
| Phosphorylation | 9 | 2014 | 1612 | 0.360 |
Why?
|
| Veterans | 8 | 2025 | 1763 | 0.350 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 926 | 0.340 |
Why?
|
| Patient Care Team | 3 | 2022 | 576 | 0.340 |
Why?
|
| Visual Fields | 1 | 2011 | 145 | 0.330 |
Why?
|
| Immunotherapy | 3 | 2011 | 749 | 0.330 |
Why?
|
| Aminopeptidases | 2 | 2006 | 15 | 0.320 |
Why?
|
| Movement Disorders | 2 | 2009 | 223 | 0.320 |
Why?
|
| Protein Multimerization | 5 | 2013 | 151 | 0.320 |
Why?
|
| Vision Disorders | 1 | 2011 | 217 | 0.310 |
Why?
|
| Neurons | 5 | 2016 | 2012 | 0.310 |
Why?
|
| Mutation | 9 | 2014 | 6250 | 0.310 |
Why?
|
| Dopamine | 2 | 2009 | 253 | 0.300 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2008 | 11 | 0.300 |
Why?
|
| Diabetic Retinopathy | 1 | 2011 | 168 | 0.300 |
Why?
|
| Aged | 16 | 2025 | 21482 | 0.300 |
Why?
|
| Specialization | 1 | 2009 | 80 | 0.300 |
Why?
|
| Models, Genetic | 2 | 2016 | 771 | 0.290 |
Why?
|
| Medicine | 1 | 2009 | 106 | 0.280 |
Why?
|
| Brain | 7 | 2016 | 3194 | 0.280 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2009 | 375 | 0.280 |
Why?
|
| Genes, Dominant | 1 | 2008 | 251 | 0.270 |
Why?
|
| Hypertension | 1 | 2016 | 1398 | 0.270 |
Why?
|
| Neurology | 1 | 2009 | 118 | 0.270 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1541 | 0.260 |
Why?
|
| Middle Aged | 15 | 2025 | 29021 | 0.250 |
Why?
|
| Amyloidosis | 3 | 2011 | 73 | 0.240 |
Why?
|
| Frontal Lobe | 3 | 2015 | 120 | 0.240 |
Why?
|
| Skin Diseases | 3 | 2011 | 136 | 0.240 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2025 | 6 | 0.230 |
Why?
|
| Male | 22 | 2025 | 65012 | 0.230 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 10 | 0.230 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2025 | 17 | 0.220 |
Why?
|
| Lewy Body Disease | 2 | 2015 | 21 | 0.220 |
Why?
|
| Pastoral Care | 2 | 2014 | 3 | 0.210 |
Why?
|
| Colorectal Neoplasms | 3 | 2016 | 630 | 0.210 |
Why?
|
| Female | 20 | 2025 | 70785 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2009 | 554 | 0.200 |
Why?
|
| United States | 9 | 2023 | 11669 | 0.200 |
Why?
|
| Quality Improvement | 3 | 2023 | 700 | 0.200 |
Why?
|
| Inappropriate Prescribing | 1 | 2023 | 38 | 0.200 |
Why?
|
| Glycerol | 2 | 2013 | 82 | 0.190 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2011 | 61 | 0.190 |
Why?
|
| Amyloid | 3 | 2011 | 70 | 0.190 |
Why?
|
| Cell Death | 3 | 2016 | 243 | 0.190 |
Why?
|
| Photoreceptor Cells, Invertebrate | 1 | 2002 | 59 | 0.180 |
Why?
|
| Insect Proteins | 1 | 2002 | 111 | 0.180 |
Why?
|
| Hospitals, Veterans | 2 | 2014 | 348 | 0.180 |
Why?
|
| Trans-Activators | 2 | 2002 | 712 | 0.180 |
Why?
|
| Eye Abnormalities | 1 | 2002 | 104 | 0.180 |
Why?
|
| Physician-Patient Relations | 1 | 2025 | 447 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 241 | 0.170 |
Why?
|
| Mutation, Missense | 3 | 2013 | 937 | 0.170 |
Why?
|
| Nervous System Malformations | 1 | 2002 | 132 | 0.170 |
Why?
|
| Mental Health Services | 2 | 2014 | 281 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1597 | 0.170 |
Why?
|
| Brain Concussion | 1 | 2022 | 238 | 0.160 |
Why?
|
| Iron Chelating Agents | 1 | 2019 | 15 | 0.160 |
Why?
|
| Antibodies | 4 | 2015 | 366 | 0.140 |
Why?
|
| Phenotype | 4 | 2016 | 4540 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2019 | 201 | 0.140 |
Why?
|
| Protein Binding | 2 | 2014 | 1734 | 0.130 |
Why?
|
| Hand Strength | 1 | 2017 | 61 | 0.130 |
Why?
|
| Organizational Innovation | 1 | 2017 | 48 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2017 | 38 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 82 | 0.130 |
Why?
|
| Health Personnel | 1 | 2022 | 545 | 0.130 |
Why?
|
| Glycerol Kinase | 2 | 2013 | 19 | 0.130 |
Why?
|
| Iron | 1 | 2019 | 302 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 516 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 23 | 0.130 |
Why?
|
| Incidental Findings | 1 | 2017 | 131 | 0.120 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2016 | 56 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 1718 | 0.120 |
Why?
|
| Blast Injuries | 1 | 2016 | 61 | 0.120 |
Why?
|
| Proteins | 3 | 2006 | 1038 | 0.120 |
Why?
|
| Age Factors | 2 | 2016 | 2923 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 651 | 0.120 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2016 | 50 | 0.120 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 606 | 0.120 |
Why?
|
| Life Style | 1 | 2018 | 453 | 0.120 |
Why?
|
| Veterans Health | 1 | 2017 | 179 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2011 | 618 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 456 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 213 | 0.110 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2014 | 15 | 0.110 |
Why?
|
| Exercise Test | 1 | 2015 | 256 | 0.110 |
Why?
|
| RNA Interference | 2 | 2013 | 515 | 0.110 |
Why?
|
| Connectome | 1 | 2016 | 119 | 0.110 |
Why?
|
| Transgenes | 2 | 2008 | 336 | 0.110 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2014 | 36 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2017 | 821 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2016 | 800 | 0.110 |
Why?
|
| Comprehensive Health Care | 1 | 2014 | 17 | 0.110 |
Why?
|
| Retina | 2 | 2016 | 491 | 0.110 |
Why?
|
| Imaginal Discs | 1 | 2013 | 11 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 3691 | 0.100 |
Why?
|
| Behavior Therapy | 1 | 2016 | 269 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 3995 | 0.100 |
Why?
|
| Immunization, Passive | 1 | 2014 | 128 | 0.100 |
Why?
|
| Medication Errors | 1 | 2016 | 205 | 0.100 |
Why?
|
| RNA | 1 | 2017 | 552 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 398 | 0.100 |
Why?
|
| United States Department of Defense | 1 | 2013 | 9 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 2442 | 0.100 |
Why?
|
| Patient Selection | 1 | 2017 | 731 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2014 | 168 | 0.100 |
Why?
|
| Heart Rate | 1 | 2015 | 584 | 0.100 |
Why?
|
| Sex Factors | 1 | 2016 | 1354 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 857 | 0.090 |
Why?
|
| Adult | 5 | 2016 | 31614 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2002 | 2491 | 0.090 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 301 | 0.090 |
Why?
|
| Apoptosis | 2 | 2014 | 1901 | 0.090 |
Why?
|
| Biopolymers | 1 | 2012 | 21 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2014 | 244 | 0.090 |
Why?
|
| Retinal Photoreceptor Cell Outer Segment | 1 | 2011 | 8 | 0.090 |
Why?
|
| Sirolimus | 1 | 2014 | 241 | 0.090 |
Why?
|
| Contrast Sensitivity | 1 | 2011 | 43 | 0.090 |
Why?
|
| Dark Adaptation | 1 | 2011 | 36 | 0.090 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 12 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2011 | 15 | 0.090 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 1 | 2012 | 39 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 24 | 0.090 |
Why?
|
| Young Adult | 3 | 2016 | 9966 | 0.090 |
Why?
|
| Visual Field Tests | 1 | 2011 | 52 | 0.090 |
Why?
|
| Mice | 10 | 2014 | 18507 | 0.090 |
Why?
|
| Amyloidogenic Proteins | 1 | 2011 | 7 | 0.090 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 2451 | 0.090 |
Why?
|
| Rats | 3 | 2013 | 3607 | 0.090 |
Why?
|
| Biological Assay | 1 | 2012 | 111 | 0.090 |
Why?
|
| Neurotoxins | 1 | 2011 | 58 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 125 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 117 | 0.090 |
Why?
|
| Osteitis Deformans | 1 | 2011 | 9 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 142 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2011 | 115 | 0.090 |
Why?
|
| Proteostasis Deficiencies | 1 | 2010 | 7 | 0.080 |
Why?
|
| Genes, Lethal | 2 | 2013 | 77 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 482 | 0.080 |
Why?
|
| Myositis, Inclusion Body | 1 | 2011 | 55 | 0.080 |
Why?
|
| Exercise | 1 | 2016 | 860 | 0.080 |
Why?
|
| Genotype | 2 | 2014 | 2703 | 0.080 |
Why?
|
| Frontotemporal Dementia | 1 | 2011 | 74 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 275 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2015 | 1402 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 2012 | 196 | 0.080 |
Why?
|
| Alzheimer Vaccines | 1 | 2009 | 1 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2025 | 1444 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 484 | 0.080 |
Why?
|
| Repetitive Sequences, Amino Acid | 2 | 2006 | 19 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2166 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2006 | 469 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 398 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1966 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 7138 | 0.070 |
Why?
|
| Immunization | 1 | 2010 | 312 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 486 | 0.070 |
Why?
|
| Microtubules | 1 | 2008 | 125 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2013 | 716 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 826 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2011 | 707 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 126 | 0.070 |
Why?
|
| Huntingtin Protein | 2 | 2004 | 64 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 1134 | 0.070 |
Why?
|
| Hippocampus | 1 | 2012 | 820 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 1285 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 685 | 0.060 |
Why?
|
| Cell Count | 1 | 2007 | 234 | 0.060 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 101 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2006 | 252 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2010 | 408 | 0.060 |
Why?
|
| Computational Biology | 1 | 2011 | 876 | 0.060 |
Why?
|
| Exons | 2 | 2008 | 806 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1168 | 0.060 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2004 | 12 | 0.060 |
Why?
|
| Trinucleotide Repeats | 1 | 2005 | 109 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 491 | 0.060 |
Why?
|
| Vaccines | 1 | 2010 | 381 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2004 | 141 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 340 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2006 | 1080 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 3404 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 377 | 0.050 |
Why?
|
| Caspases | 1 | 2004 | 166 | 0.050 |
Why?
|
| Polysomnography | 1 | 2025 | 155 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 861 | 0.050 |
Why?
|
| Dementia | 1 | 2008 | 475 | 0.050 |
Why?
|
| Gene Expression | 1 | 2008 | 1563 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 1045 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2008 | 1050 | 0.050 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2002 | 6 | 0.050 |
Why?
|
| Armadillo Domain Proteins | 1 | 2002 | 9 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 1350 | 0.050 |
Why?
|
| Primidone | 1 | 2022 | 9 | 0.050 |
Why?
|
| High Mobility Group Proteins | 1 | 2002 | 33 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2002 | 46 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 166 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2002 | 105 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 112 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1418 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2001 | 86 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 282 | 0.040 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 315 | 0.040 |
Why?
|
| beta Catenin | 1 | 2002 | 227 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2002 | 813 | 0.040 |
Why?
|
| Glutamine | 1 | 2001 | 211 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2012 | 826 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 273 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 2851 | 0.040 |
Why?
|
| Caregivers | 1 | 2025 | 596 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1883 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 982 | 0.040 |
Why?
|
| Neuroblastoma | 2 | 2014 | 550 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 589 | 0.040 |
Why?
|
| Registries | 2 | 2016 | 1591 | 0.030 |
Why?
|
| Adolescent | 1 | 2016 | 20557 | 0.030 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 674 | 0.030 |
Why?
|
| Microelectrodes | 1 | 2016 | 43 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 1445 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 138 | 0.030 |
Why?
|
| Electroretinography | 1 | 2016 | 121 | 0.030 |
Why?
|
| Globus Pallidus | 1 | 2016 | 69 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 67 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2008 | 4720 | 0.030 |
Why?
|
| Vision, Ocular | 1 | 2016 | 132 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2016 | 303 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1186 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 220 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 116 | 0.030 |
Why?
|
| Clergy | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cellular Structures | 1 | 2014 | 2 | 0.030 |
Why?
|
| Prions | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2015 | 105 | 0.030 |
Why?
|
| Myelin Basic Protein | 1 | 2014 | 67 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2016 | 222 | 0.030 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 2013 | 4 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 764 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 196 | 0.030 |
Why?
|
| Wings, Animal | 1 | 2013 | 35 | 0.030 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2013 | 18 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 230 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2012 | 60 | 0.020 |
Why?
|
| Health Surveys | 1 | 2014 | 260 | 0.020 |
Why?
|
| Larva | 1 | 2013 | 260 | 0.020 |
Why?
|
| Solutions | 1 | 2012 | 59 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 65 | 0.020 |
Why?
|
| Hypoadrenocorticism, Familial | 1 | 2012 | 1 | 0.020 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2012 | 36 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 143 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2012 | 118 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2012 | 110 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2011 | 11 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 380 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2011 | 29 | 0.020 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2011 | 12 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 2012 | 83 | 0.020 |
Why?
|
| Hematoxylin | 1 | 2011 | 8 | 0.020 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2011 | 9 | 0.020 |
Why?
|
| Congo Red | 1 | 2011 | 7 | 0.020 |
Why?
|
| Birefringence | 1 | 2011 | 12 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2012 | 72 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2011 | 11 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 62 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2011 | 31 | 0.020 |
Why?
|
| Dermis | 1 | 2011 | 26 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2014 | 375 | 0.020 |
Why?
|
| Valosin Containing Protein | 1 | 2011 | 13 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2011 | 76 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 237 | 0.020 |
Why?
|
| Epidermis | 1 | 2011 | 64 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 172 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 636 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 201 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 120 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 4758 | 0.020 |
Why?
|
| Thiazoles | 1 | 2011 | 99 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2010 | 31 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2010 | 11 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 47 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 181 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1255 | 0.020 |
Why?
|
| Protein Folding | 1 | 2011 | 224 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1444 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2011 | 141 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 246 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 153 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2010 | 76 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1224 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17395 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2011 | 198 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1008 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2010 | 190 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 541 | 0.020 |
Why?
|
| Endopeptidase K | 1 | 2009 | 4 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 3018 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2009 | 35 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2013 | 662 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2011 | 472 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2009 | 92 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1725 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 209 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2009 | 96 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3376 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1170 | 0.020 |
Why?
|
| Introns | 1 | 2008 | 305 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2233 | 0.020 |
Why?
|
| Puromycin | 1 | 2006 | 12 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 862 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 996 | 0.020 |
Why?
|
| Macrophages | 1 | 2011 | 692 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2196 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5410 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 1288 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 618 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 826 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 1685 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 1121 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 1233 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 2724 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 90 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2009 | 927 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 590 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3761 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 268 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 1284 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1130 | 0.010 |
Why?
|
| Models, Animal | 1 | 2006 | 469 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3853 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2005 | 195 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 454 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 317 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 651 | 0.010 |
Why?
|
| Fetal Development | 1 | 2005 | 131 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 2161 | 0.010 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2001 | 4 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2001 | 28 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2001 | 77 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 58 | 0.010 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2001 | 52 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3414 | 0.010 |
Why?
|
| Acetylation | 1 | 2001 | 191 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 142 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2001 | 122 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2001 | 227 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2669 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 2900 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3771 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2680 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 13027 | 0.010 |
Why?
|
| Histones | 1 | 2001 | 535 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 3358 | 0.010 |
Why?
|